Campath in Chronic GVHD
NCT00495755
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
13
Enrollment
OTHER
Sponsor class
Conditions
Chronic Graft-vs.-Host Disease
Interventions
DRUG:
Alemtuzumab (Campath)
Sponsor
Dana-Farber Cancer Institute
Collaborators
[object Object]
[object Object]